ABG
CMPX icon

Ally Bridge Group’s Compass Therapeutics CMPX Stock Holding History

Ally Bridge Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-834,630
Closed -$1.3M – 27
2023
Q4 		$1.3M Sell
834,630
-80,000
-9% -$138K 0.78% 19
2023
Q3 		$1.8M Hold
914,630
– – 2.11% 16
2023
Q2 		$2.91M Buy
+914,630
New +$2.87M 3.52% 13

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ally Bridge Group's CMPX Position: Q1 2024 in Review

Ally Bridge Group sold out of Compass Therapeutics (CMPX) in Q1 2024, closing a stake of 834,630 shares — an estimated $1.3M sold.

Ally Bridge Group first reported a position in CMPX in Q2 2023 and held it in 3 quarters. The position peaked at $2.91M in Q2 2023. 78 funds tracked by Wall St. Rank hold CMPX as of Q1 2024.

  • Ally Bridge Group reported no remaining Compass Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ally Bridge Group sold 834,630 Compass Therapeutics shares in Q1 2024, an estimated $1.3M.
  • Ally Bridge Group first reported a position in Compass Therapeutics in Q2 2023 and held it in 3 quarters.
  • Ally Bridge Group's Compass Therapeutics position peaked at $2.91M in Q2 2023.
  • 78 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2024.

Based on Ally Bridge Group's 13F filing for Q1 2024, filed 15 May 2024.